entertainment -WSS

entertainment

author：hotspot 2025-10-02 22:58:26 - browse：56927

Sanofi, the Paris-based drug giant, announced Friday that it would spin out its $5 billion consumer health division, which is exploring over-the-counter moves for the erectile dysfunction drug Cialis and the flu treatment Tamiflu.

Investors reacted swiftly, bidding Sanofi’s American depository receipts on the New York Stock Exchange down nearly 18% to less than $44 in morning trading. Jared Holz, an analyst at Mizuho, warned investors that the drop “would be the largest negative single-day stock move across Global Pharma in more than ten years.”

It would be tempting to take the stock move as evidence that investors have finally tired of watching drug companies treat consumer product divisions like baseball trading cards, buying them at a high price only to sell them again a decade later. But the move probably has little to do with the current passion for pharma spinouts or with Sanofi following in the footsteps of GSK, Novartis, and Pfizer in shedding a division. Or even, for that matter, Sanofi, which shed its pharmaceutical ingredients business, EuroAPI, which is now trading at a third of its initial public offering price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Eli Lilly, Pfizer, and others want in on the online prescription market

entertainment

WSS

Alexander Hamilton and the argument for universal insurance

'The boss' wants server deleted: New allegations emerge in Trump indictment

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Test for long Covid? Researchers find new clue in blood samples

Biotech venture capitalists face new demands from investors

Independent physicians launch a new lobbying group

hotspot

entertainment

entertainment

Moonlake's readout produced a cash windfall. Risks remain

Ending health disparities requires full federal government, panel says

Jerome Adams on the need for new antivirals for Covid

Timeline: Special counsel's probe into Trump's handling of classified documents

Bright Health sells Medicare Advantage business to Molina

FDA clears AI tool for detecting skin cancer

In age of alternative facts, a scholarly course on calling out crap

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

In Memoriam: Notable people who died in 2023

Parkinson’s finding may lead to tests and, someday, treatments

leisure time

Stoke drug shows lower activity against childhood epilepsy

The Jan. 6 committee previously recommended Trump be criminally charged. Here's why

Elizabeth Holmes banned from government health programs

The mammogram wars are not over

Alexander Hamilton and the argument for universal insurance

VC firm RA Capital starts a new synthetic biology incubator

entertainment

entertainment

hotspot

knowledge